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Abstract: OBJECTIVE: The aim of this study was to determine the predictive value of machine perfusate
analysis on graft outcome. BACKGROUND: Ex situ machine perfusion (MP) is gaining increasing inter-
est to potentially repair injured organs and to assess organ function. In the field of liver transplantation,
however, no studies exist on reliable prediction of graft function during MP. METHODS: We have used
hypothermic oxygenated perfusion (HOPE) for donation after circulatory death (DCD) or extended cri-
teria donation after brain death (DBD) human liver grafts during the last 7 years. Our series includes 100
HOPE-treated liver-transplanted patients with an overall tumor-censored 5-year graft survival of 89%.
We monitored 54 livers during HOPE in terms of fluorometric analysis of released mitochondrial flavin
(flavin mononucleotide, FMN) in the machine perfusate. RESULTS: Real-time optical measurement of
mitochondrial FMN release in machine perfusates of livers disclosed a strong correlation with lactate
clearance and coagulation factors at day 1 and 2 after transplantation. Receiver-operating character-
istic curve analysis revealed an area under the curve (AUROC) of 0.79 [95% confidence interval (CI),
0.62-0.97] for severe allograft dysfunction and for early graft loss (AUROC 0.93, 95% CI, 0.84-1.0). CON-
CLUSIONS: Assessment of flavin, a marker of mitochondrial complex I injury, in the perfusate provides
a fast prediction of liver graft function and loss during ex situ MP before implantation. This finding may
have high clinical relevance, as liver grafts from extended DBD or DCD donors carry considerable risks
for recipients. On-line estimation of outcome before implantation would therefore substantially increase
safe utilization of liver grafts.
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Objective: The aim of this study was to determine the predictive value of
machine perfusate analysis on graft outcome.
Background: Ex situ machine perfusion (MP) is gaining increasing interest
to potentially repair injured organs and to assess organ function. In the field of
liver transplantation, however, no studies exist on reliable prediction of graft
function during MP.
Methods: We have used hypothermic oxygenated perfusion (HOPE) for
donation after circulatory death (DCD) or extended criteria donation after
brain death (DBD) human liver grafts during the last 7 years. Our series
includes 100 HOPE-treated liver-transplanted patients with an overall tumor-
censored 5-year graft survival of 89%. We monitored 54 livers during HOPE
in terms of fluorometric analysis of released mitochondrial flavin (flavin
mononucleotide, FMN) in the machine perfusate.
Results: Real-time optical measurement of mitochondrial FMN release in
machine perfusates of livers disclosed a strong correlation with lactate
clearance and coagulation factors at day 1 and 2 after transplantation.
Receiver-operating characteristic curve analysis revealed an area under the
curve (AUROC) of 0.79 [95% confidence interval (CI), 0.62–0.97] for
severe allograft dysfunction and for early graft loss (AUROC 0.93, 95%
CI, 0.84–1.0).
Conclusions: Assessment of flavin, a marker of mitochondrial complex I
injury, in the perfusate provides a fast prediction of liver graft function and
loss during ex situ MP before implantation. This finding may have high
clinical relevance, as liver grafts from extended DBD or DCD donors carry
considerable risks for recipients. On-line estimation of outcome before
implantation would therefore substantially increase safe utilization of liver
grafts.
Keywords: complex I, FMN, hypothermic oxygenated perfusion, liver
transplantation
(Ann Surg 2019;270:783–790)
T he assessment of graft quality has always been considered as keyconfounder for outcome since the early days of liver transplan-
tation (LT).1 However, still today the assessment of liver quality and
the decision to accept or decline a graft before transplantation mostly
relies on ‘‘gut feeling,’’ in combination with donor demographics and
medical history.2,3
Machine perfusion (MP) before implantation offers the unique
opportunity to develop objective evaluation tools to assess the
metabolic status and degree of injury of an organ. Until recently,
only a few parameters for metabolic and cellular damage have been
quantified in machine liver perfusates including lactate, transami-
nases, and pH, besides assessing bile production and bile quality.2,4,5
Two emerging studies looked at the predictive value of novel markers
through metabolomics and glyconomics6–8 suggesting superior clin-
ical relevance of specific metabolic pathways in the liver, compared
to the quantification of released cytosolic compounds.9,10
Since 2012, hypothermic oxygenated perfusion (HOPE) was
routinely used in our center to improve human liver grafts donated
after circulatory death (DCD) before implantation.11 Despite
extended functional donor warm ischemia time in our DCD cohort,
the outcomes have been excellent, along with significant changes of
the mitochondrial metabolism with subsequent recharging of cellular
energy indicating mitigated ischemia-reperfusion injury.12,13
In this study, wemonitored changes in the perfusate of specific
mitochondrial metabolisms during HOPE to identify novel
markers with robust predictive value for graft function after liver
implantation.
METHODS
Patient Cohort and Parameters of Donor Surgery,
MP and Graft Implantation
We present here the entire cohort of machine perfused human
liver grafts transplanted at our center between 2012 and 2018. A
detailed perfusate analysis was performed in the last 54 perfused
grafts of this series, e.g. since 2016. Donation after brain death
(DBD) livers were procured by the standard retrieval approach with
cold in situ flush using Institute-George-Lopez-1 (IGL-1) solution. In
contrast, DCD livers were procured using the super rapid retrieval
technique, followed by cold storage and transport. HOPE treatment
of liver grafts was always performed end-ischemically, that is, after
cold storage. Livers were perfused as previously reported through the
portal vein only using the Liver Assist device (Organ Assist) with a
portal vein pressure limit at 3mm Hg resulting in low portal flows
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(range:150–300mL/min). Three litres of highly oxygenated (80–
100 kPa) University of Wisconsin MP solution (Belzer-MPS) were
used to perfuse all livers, and the perfusate was never exchanged
during perfusion. HOPE was performed during recipient hepatec-
tomy for at least 1 hour. The routine technique for liver implantation
used at our center is the classic cava-replacement technique without
the use of veno-venous bypass. Liver reperfusion was done through
the portal vein first, followed by subsequent arterial reperfusion.
Machine-perfused livers were allocated to candidates with hepato-
cellular carcinoma (HCC) and subsequent low Model of end-stage
liver disease (MELD) score, with an expected long waiting time; the
respective donor and recipient characteristics are illustrated in
Supplementary Table 1, http://links.lww.com/SLA/B719.
Perfusate Analysis During MPHOPE
We measured the following parameters in the perfusate of
HOPE treated livers:
1. Lactate and glucose levels in the perfusate were measured real-
time during perfusion using the Radiometer ABL800 Flex device.
In addition, the concentration of aspartate aminotransferase
(AST), alanine aminotransferase (ALT), and lactate dehydroge-
nase (LDH) perfusate levels was measured (real-time), using the
FujiFilm Dri-CHEm 4000i device.
2. Nicotine adenine dinucleotide (NAD), succinic acid, inosine
monophosphate (IMP), hypoxanthine, and noncovalently bound
mitochondrial flavin (flavin mononucleotide, FMN) were deter-
mined by targeted liquid chromatography-mass spectroscopy.
3. FMN was further determined by fluorescence spectroscopy. In
detail, a light probe was connected to a halogen light source to
emit monochrome light at a wavelength of 450 nm on the
circulating perfusate. A spectrometric receiver probe with suffi-
ciently high resolution (eg, 4.6 nm) was used to quantify the
proportion of emitted fluorescent light by the FMNmolecule. The
fluorescence emission maximum of FMN was measured between
500 and 600 nm. Measurement of the fluorescence takes only
seconds, and the final value is instantly displayed on a monitor.
Endpoints
Perfusate measurements were correlated to post-transplant
arterial lactate clearance, international normalized ratio, INR,
factor V, liver transaminases, hospital stay, and complications using
the comprehensive complication index as the novel metric for mor-
bidity until discharge from hospital, and graft loss was recorded until
3 months after LT. Models to assess donor liver quality [donor risk
index (DRI) anddonor liver index (DLI)] andother composite scores of
early allograft function such as early allograft dysfunction (EAD),
defined by Olthof et al14 or the L-Graft score, defined by Agopian
et al15 were correlated with perfusate metabolites and outcomes.
The local ethic committee approved the study protocol (KEK-
No. 2015–0200 and KEK No. 2019-01000).
Statistical Analysis
Statistical analysis was performed using the SPSS statistical
software package (SPSS, version 20, IBM, Armonk, NY) and Graph


















Overall DBD DCD P value DBD 
vs. DCD
AST (U) 456 (196-1108) 196 (92-348) 742 (292-1490) 0.0042
ALT (U) 748 (296-1484) 316 (154-740) 1008 (481-1913) 0.0046
LDH (U) 3236 (976-7160) 1124 (332-3284) 5240 (2158-10245) 0.0014
Lactate (mmol/l) 3.05 (2-3.775) 2.7 (1.85-3.45) 3.4 (2.0-5.03) 0.3814







FMN 30 min (A.U.) 5889 (4872-7022) 5547 (4260-6111) 6973 (5363-9575) 0.0007
FMN end of HOPE (A.U) 6598 (4886-8684) 4820 (4127-6206) 7889 (6130-10933) 0.0002
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FIGURE 1. Example of HOPE-treatment of human liver (A) and perfusate parameters in 54 HOPE-treated DCD and DBD livers (B).
Correlation of perfusate FMN with perfusate AST, ALT, lactate, and LDH (C–F).
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values and interquartile ranges, and categorical variables were
expressed in percentages. Normality of the distribution of variables
was tested using QQ plots and the Kolmogorov–Smirnoff test. Graft
failure–free survival and overall patient survival curves were com-
puted using Kaplan–Meier curves. Correlations between fluorimet-
ric perfusate analysis and liver graft function were calculated using
Pearson correlation coefficient (R). Reference values for strength of
effect size were: ‘‘very weak’’ 0.00–0.19, ‘‘weak’’ 0.20–0.39,
‘‘moderate’’ 0.40–0.59, ‘‘strong’’ 0.60–0.79, and ‘‘very strong’’
0.80–1.0. Sensitivity and specificity of the predictive value of
FMN was tested using receiver-operating characteristic curve
(ROC) analysis. Cut-offs for highest specificity and sensitivity were
determined by the Youden index. Tests were considered statistically
significant at a 2-sided P value of <0.05.
RESULTS
Donor and Recipient Risks in HOPE-Treated Liver
Cohort
During the study period, a total of 100 liver grafts (80 DCD, 20
DBD) underwent HOPE for a median of 120 minutes (91–
150minutes) followed by LT. (Supplementary Table 1, http://link-
s.lww.com/SLA/B719). All DCD machine-perfused liver grafts
showed a high-risk profile, as depicted by several current risk scores.
For example, half of the DCD livers were classified into the futile
group of the UK DCD risk score with a median of 10 points.16 In
addition, one-third of our donor livers (DBD and DCD) showed 10%
to 30% macrosteatosis in biopsies (Supplementary Figure 1A, http://
links.lww.com/SLA/B719). The DLI and DRI were consecutively
higher than 2.2 points for DCD livers, and higher than 1.6 for DBD
livers, far above recent reported median values in UK cohorts.17–19
To compensate for inferior graft quality, cold ischemia time (median
4.8 hours) and recipient MELD (median 13 points) were kept as low
as possible (HCC recipients). However, in the last 2 years, extended
DCD liver grafts were also used for retransplantations and to
‘‘rescue,’’ for example, high MELD candidates (Supplementary
Figure 1B, http://links.lww.com/SLA/B719). Of note, DBD grafts
included in the study were from extended criteria donor, with half
being 60 years’ old and 20% presenting a BMI >30 kg/m2. After
HOPE treatment, these grafts were also primarily allocated to
recipients with HCC presenting, however, a slightly higher MELD
score than the DCD recipients (16 vs 12 points) (Supplementary
Table 1, http://links.lww.com/SLA/B719).
Despite an overall high-risk population in our cohort, graft
survival, censored for tumor-related death, remained comparable
to the benchmark level for an ideal LT, for exampl, 89% at 1 and
5 years.20 In total, we lost 7 of 100 grafts in the first 3months
after transplantation because of hepatic artery thrombosis (1%),
































































































Peak ALT first week after OLT (U)
R=0.6389
p<0.0001
Perfusate FMN / lactate Perfusate FMN / lactate Perfusate FMN / lactate Perfusate FMN / INR
Perfusate FMN / INR Perfusate FMN / factor V Perfusate FMN / Factor V Perfusate FMN / peak ALT
FIGURE 2. Correlation of perfusate FMN with post-transplant lab parameters of liver function and injury, such as arterial lactate
(A–C), INR (D and E), and factor V (F and G), peak ALT (H).
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Prediction of Graft Function
We performed a detailed perfusate analysis in 54 HOPE-
treated livers (19 DBD, 35 DCD livers). Real-time fluorometric
measurements during MP were validated with mass spectroscopy
(Supplementary Figure 1B, http://links.lww.com/SLA/B719). The
results show, first, clear differences between DBD and DCD livers in
terms of perfusate AST, ALT, LDH levels, and FMN, in contrast to
perfusate succinate and lactate (Fig. 1B). Of note, the release of liver
transaminases from DCD livers into the perfusate during HOPE was
significantly lower (median AST 742U/L, median ALT U/L 1008)
(Fig. 1B), when compared to previous published values from DCD
livers during end-ischemic normothermic perfusion.2,21 Second, the
release of mitochondrial flavin, for example, FMN, occurred inde-
pendently from the release of cytosolic hepatocellular enzymes, for
example, AST, ALT, or LDH, consistent with a mitochondrial origin
of FMN (Fig. 1C, D, F). Third, we found a strong correlation of
FMN release with coagulation factors and peak transaminases after
LT (R > 0.6) (Fig. 2A–H), whereas conventional perfusate param-
eters, including AST and ALT, correlated with peak transaminases
after LT, but failed to predict liver graft function (Supplementary
Figure 2, http://links.lww.com/SLA/B719, Supplementary Table 2,
http://links. lww.com/SLA/B719).
Furthermore, perfusate FMN appeared clinically relevant, as
we found a correlation with hospital stay and more importantly with
cumulative complications after LT, in contrast to other perfusate
values (Fig. 3A–C). FMN analysis in machine perfusate was also
predictive for both, early allograft dysfunction [c statistic 0.72, 95%
confidence interval (CI), 0.57–0.86], defined by Olthof et al, and for
high-risk grafts, defined by the L-Graft score (c statistic 0.79, 95%
CI, 0.62–0.97) (Supplementary Figure 3, http://links.lww.com/SLA/
B719).We consecutively grouped machine-perfused livers according
to their FMN release within the first 30 minutes of HOPE in 2 risk
groups, for example, low and high FMN perfusate. Perfusate mass
spectroscopy revealed that high FMN release correlated significantly
with higher perfusate concentrations of electron donors, for example,
NAD, and purine metabolites, for example, IMP and hypoxanthine.
In contrast, perfusate succinate decreased with higher FMN release
(Fig. 4A–E). This inverse relationship of perfusate succinate and
purine metabolites points to inhibition of mitochondrial electron
transfer between complex I and II, and allows ‘‘on line’’ recognition
of mitochondrial injury, based on the amount of FMN, released into
cold perfusate.
Prediction of Early Graft Loss
High perfusate FMN correlated also with graft loss within
3 months after LT, and revealed higher predictability (area under the
ROC curve 0.93, 95% CI, 0.84–1.0) than any other available scores,
such as DRI, DLI, and L-Graft (Fig. 5A–D). The threshold for
highest accuracy in terms of early graft loss was identified at 10000
A.U, e.g. 100 ng FMN/ml perfusate. Of note, perfusate ASTand ALT
also showed high c-statistics, whereas perfusate lactate und glucose










Correlaon of Perfusate Parameters with outcome R P value
7700.074.0yatS latipsoH dna nim 03 NMF
1000.0<2085.0eninitaerC kaeP dna nim 03 NMF
1000.0<86.0yats latipsoh gnirud ICC dna nim 03 NMF
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3306.017480.0eninitaerC kaeP dna TLA
7770.09172.0yats latipsoh gnirud ICC dna TLA
4267.008950.0yatS latipsoH dna etatcaL
3201.02123.0eninitaerC kaeP dna etatcaL
5843.03471.0yats latipsoh gnirud ICC dna etatcaL
Perfusate FMN / hospital stay Perfusate FMN / peak creanine Perfusate FMN / CCI at discharge
FIGURE 3. Correlation of perfusate FMN, AST, ALT, and lactate with hospital stay, kidney function, and overall complications
(comprehensive complication index).
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DISCUSSION
To our knowledge, this is the first report on prediction of graft
function and early graft loss by perfusate analysis during cold
perfusion of human livers. We show an accurate and readily available
prediction of liver viability during ex situ MP before implantation,
based on the level of mitochondrial complex I injury through
quantification of FMN in perfusate. This marker disclosed
superiority compared to conventional parameters for liver viability.
We expect a high clinical relevance of these results, as liver grafts
from marginal DBD or extended DCD donors carry considerable
risks for the recipients. Reliable on-line estimation of outcome before
implantation would therefore substantially increase the safe utiliza-
tion of liver grafts.
MP strategies receive increasing attention in the field of
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FIGURE 5. ROC analysis of perfusate FMN, DRI, DLI, L-Graft score, perfusate AST, ALT, glucose, and lactate on 90-day graft loss.
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graft quality before implantation.22However, current viability tests
during perfusion target mostly lactate clearance, release of hepa-
tocellular enzymes, or bile production, which all have been
found to be weak parameters predicting later liver function.2,3 In
contrast, we demonstrate that monitoring of mitochondrial injury
during cold oxygenated perfusion is not only feasible, but serves
as reliable parameter for functional recovery of livers during
implantation.
The strength of a cold oxygenated perfusion approach appears
2-fold. First, because of the lower demand of energetic substances in
the cold, oxygen carriers are not needed during hypothermic liver
perfusion.11,23,24 Acelluar perfusates with dissolved oxygen appear
therefore sufficient for maintaining mitochondrial function during
hypothermia or sub-normothermia, with the simultaneous major
advantage for implementation of novel optical measurements or
even treatment during perfusion, for example by eradication of
hepatitis C by short wave ultraviolet light.25 Second, reactive oxygen
species are significantly less produced during cold oxygenation of
ischemic liver cells, as compared to normothermic conditions.
Consistently, AST/ALT release in the perfusate during HOPE of
high-risk DCD grafts was less than the release observed during
normothermic perfusion.26,27 Hypothermic oxygenated perfusion
offers therefore not only protection from reperfusion injury with
subsequently improved liver function, but may serve as prediction
tool for early graft function in the recipient.
Our results based on the new finding of a small compound,
FMN, released from the first electron transferring mitochondrial
protein during oxygenated perfusion. Complex I is a sophisticated
mitochondrial protein, containing 8 iron–sulphur clusters and non-
covalently bound FMN.28 This complex uses 2 substrates, NADH
and ubiquinone, and couples the energy of oxidoreduction to proton
translocation by an array of proton pumps. While under physiologic
conditions, FMN is very tightly bound, it dissociates from complex I
when the respiratory chain is halted and the ubiquinone pool is
highly reduced.28 Of note, the affinity of FMN in its pocket is
dependent on structural alterations around the FMN site, for exam-
ple, the redox potential of cluster N1a is likewise one of the
determinants of the affinity of FMN for complex I. Recent data
obtained from ischemic brain mitochondria have suggested that the
FMN site of mitochondrial complex I is primarily responsible for
the production of superoxide anions under normothermic condi-
tions, together with the simultaneous release of mitochondrial
FMN.29
The novel finding of this study is that mitochondrial FMN is
also released in ischemic livers subjected to cold re-oxygenation, and
is easily and readily detectable in acellular machine perfusates owing
to the natural fluorometric properties of FMN. Therefore, FMN
release serves as surrogate marker for impaired cellular energy
production, as high FMN release correlates with ATP-breakdown,
detectable by increased purine metabolites in machine perfusates
(Fig. 5). These results contrast with the low predictive value of
conventional perfusate parameters, such as transaminases or lactate
levels, which failed to recognize impaired liver function after
implantation. Instead of solely focusing on the release of cytosolic
compounds, future perfusate analysis should target on real-time
monitoring of mitochondrial metabolism to enable an accurate
prediction of oxidative stress and downstream activation of the
hepatic inflammasome upon transplantation. The combination of
several key mitochondrial metabolites including FMN, succinate,
xanthine, and hypoxanthine may allow future detailed assessment of
mitochondrial function of liver grafts.
The limitations of this study include the need for further
validation in other machine perfused liver cohorts. In addition,
current thresholds to refuse or accept livers remain subjective, but
a high accuracy based on ROC analysis could be identified in this
study suggesting a threshold at 10000 A.U. to refuse livers regardless
of the use of a DCD or DBD liver. Whether similar thresholds can be
confirmed in other cohorts such as steatotic livers remains to
be determined.
In summary, this study suggests that assessment of liver graft
quality is feasible and reliable during cold oxygenated perfusion.
Cold MP approaches have been frequently challenged in terms of
their presumed weakness in prediction of graft function, compared to
normothermic perfusion. This shortcoming is now circumvented by
the ability to monitor mitochondrial metabolism by perfusate analy-
sis during HOPE, and thereby enabling proper decision about
acceptance or not of high-risk grafts.
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DISCUSSANTS
Peter Schemmer (Graz, Austria):
There is growing significance in improved graft function after
MP for the preservation of livers; however, reliable predictors of the
grafts’ function after LT are still pending. In this study, the real-time
optical measurement of mitochondrial FMN release inMP perfusates
has been nicely correlated with both graft function and early graft
loss. Most of the studies focusing on parameters to characterize liver
function during MP are performed under normothermic or subnor-
mothermic conditions. To my knowledge, this is indeed the first time
that a real-time judgment of liver function is feasible under hypo-
thermic conditions. Interestingly, your results correlate well with
published data on ATP levels in liver tissue, and therefore, it might be
a promising tool for a multimodal approach to further characterize
and predict the fate of the transplanted livers during MP. With the
combination of both improved preservation and the prediction of the
function, HOPE has developed a conclusive strategy with substantial
benefits for the recipients’ safety after LT; however, it is still unclear
which livers profit the most from this.
You mentioned that DCD and DBD livers behave differently
during HOPE. Is this finding per se a discriminator for the use of
FMN analysis during MP? What is the optimal time point to
determine whether a graft is suitable for LT or not? Are there
predictive cutoff values of FMN analysis even before HOPE? The
authors focus on their findings after 30 minutes of HOPE. Has the
amount of FMN changed significantly when livers where perfused
for a longer time period? Is there a correlation between the duration
of MP and graft survival? Are there minimum and maximum time-
spans of HOPE for best graft assessment?
Despite these remaining questions, this well-conducted study
is of high importance and provides better insights into the patho-
physiological processes during HOPE, and thus, enlightens the
mystery of MP, to optimize outcome after LT by reliable ex vivo
graft evaluation.
Response From Philipp Dutkowski (Zurich,
Switzerland):
Thank you for these interesting questions. First, I think that
we should differentiate between assessment duringMP, and repair of
injured organs. While in principle, every liver graft would profit
from a reliable and quick assessment, repair is only needed in poor-
quality livers. For example, I believe that DBD livers without
relevant steatosis would rather not benefit from any MP. But, we
are sometimes surprised to see DCD livers with immediate good
function and DBD livers, which unexpectedly perform poorly.
Based on this, assessment of livers before implantation would
definitely increase safety. Therefore, at this stage, I would advise
to place every graft on a perfusionmachine for a short period of time,
to assess quality.
Regarding the optimum timeframe for mitochondrial FMN
measurement, key processes of ischemia reperfusion injury occur
within the first minutes. Based on this, I believe that the first 30
minutes of cold oxygenated perfusion would be a reliable time-
frame formeasuringmachine perfusates, as FMN does not continue
to increase in most liver perfusates after the initial 0.5 hour of
perfusion. With respect to the cases with high values of FMN after
30 minutes, I would recommend to repeat this analysis after 60
minutes. In my opinion, FMN measurements before oxygenated
MP, such as during cold storage, makes less sense because there is
no significant release of mitochondrial FMN without the action
of oxygen.
The maximum required time period of cold oxygenated MP
relates to the metabolic situation of the perfused livers. Maximum
benefit is reached when all accumulated succinate and NADH are
metabolized, and ATP pools are uploaded. Therefore, in principal, a
longer perfusion approach is required for more injured grafts, but
these are preliminary data.
Stefan Schneeberger (Innsbruck, Austria):
Congratulations on a very elegantly presented study. You did 2
things: you assessed a new methodology, and used new endpoints to
assess the validity and quality of these new parameters, which is a
good thing. I believe in your endpoints. However, did you also check
the more traditional endpoints of delayed graft function, including all
of the parameters that are traditionally used to assess this; and, does it
still have a predictive value?
My second question relates to bile duct interest. Did you do a
long-term assessment to observe any changes in MRCP and whether
there’s any predictive value of your assessment with respect to bile
duct viability?
Response From Philipp Dutkowski (Zurich,
Switzerland):
Thank you, Dr. Schneeberger, for these very good questions.
We have checked the predictive value of perfusate analysis for FMN
on early allograft dysfunction, defined by Olthoff et al, and on the L-
Graft risk score. Both parameters showed a high correlation with
perfusate FMN, in contrast to perfusate liver enzymes. Your second
question targets biliary injury. Currently, we cannot address the
prediction of perfusate FMN analysis on irreversible biliary injury,
as we only have a few cases with irreversible cholangiopathy in
our series.
Antonio D. Pinna (Abu Dhabi, United Arab Emirates):
Thank you for this great presentation. I have 1 question. Are
we going to move the transplant to after the measurement of
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riboflavin, or will we continue performing HOPE during the hepa-
tectomy?
Response From Philipp Dutkowski (Zurich,
Switzerland):
That is a very important point. When we introduced the
HOPE principle 7 years ago, we already started the recipient
hepatectomy during the MP, before perfusate analysis. Currently,
however, we avoid this practice, as the result of the perfusate
analysis can be unexpectedly high. Therefore, we clearly recom-
mend waiting for the perfusate analysis before starting the
recipient hepatectomy.
Norbert Senninger (Münster, Germany):
Why did you choose to only perform portal perfusion, rather
than performing both portal and arterial perfusion?
Response From Philipp Dutkowski (Zurich,
Switzerland):
This is related to several previous experimental studies in rat,
pig, and human livers, which confirmed an excellent perfusion of the
entire liver, including the extrahepatic bile duct, by single portal vein
perfusion. Based on this, we do not believe that an additional arterial
perfusion is needed in a cold environment, if portal perfusate is
highly oxygenated.
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